Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim

Greenwich LifeSciences (GLSI) remains a "Buy" as phase 3 FLAMINGO-01 advances in HER2-positive breast cancer with two major program updates. Open-label data from FLAMINGO-01 showed an 80% recurrence reduction in non-HLA-A*02 patients, supporting expanded protocol and potential market doubling. Company filed new patent claims based on statistically significant immune response and recurrence open-label data, potentially extending protection through 2045 if upheld.